Quintiles and ArgoMed to sell prostate device:
This article was originally published in Clinica
Quintiles Transnational has agreed a commercialisation alliance with Israeli company ArgoMed to develop its FDA-approved Thermoflex water-induced thermotherapy system to treat benign prostatic hyperplasia (BPH). Quintiles corporate ventures business, PharmaBio Development, will provide credit for ArgoMed to organise a US sales force and market the device. In addition, PharmaBio will take equity in the company, while Innovex, Quintiles' commercialisation unit, will deploy the sales force where it is required by ArgoMed. Innovex claims that it has created 19 sales forces and launched 19 new products over the past five years.